NasdaqCM - Delayed Quote USD

ImmuCell Corporation (ICCC)

5.27
-0.03
(-0.57%)
At close: May 16 at 4:00:01 PM EDT
5.27
0.00
(0.00%)
After hours: May 16 at 4:05:15 PM EDT
Loading Chart for ICCC
  • Previous Close 5.30
  • Open 5.36
  • Bid --
  • Ask --
  • Day's Range 5.21 - 5.45
  • 52 Week Range 3.34 - 5.82
  • Volume 32,156
  • Avg. Volume 21,025
  • Market Cap (intraday) 47.401M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

immucell.com

69

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ICCC

View More

Performance Overview: ICCC

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCC
2.33%
S&P 500 (^GSPC)
1.30%

1-Year Return

ICCC
9.79%
S&P 500 (^GSPC)
12.48%

3-Year Return

ICCC
36.89%
S&P 500 (^GSPC)
48.66%

5-Year Return

ICCC
26.08%
S&P 500 (^GSPC)
108.07%

Compare To: ICCC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ICCC

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    47.40M

  • Enterprise Value

    58.74M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.62

  • Price/Book (mrq)

    1.72

  • Enterprise Value/Revenue

    2.22

  • Enterprise Value/EBITDA

    55.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.99%

  • Return on Assets (ttm)

    0.26%

  • Return on Equity (ttm)

    -1.01%

  • Revenue (ttm)

    27.3M

  • Net Income Avi to Common (ttm)

    -271.78k

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.6M

  • Total Debt/Equity (mrq)

    50.56%

  • Levered Free Cash Flow (ttm)

    992.86k

Research Analysis: ICCC

View More

Company Insights: ICCC

Research Reports: ICCC

View More

People Also Watch